J&J Profit, Sales Beat While Currency Hit Weighs on Outlook
- CFO says revenue forecast cut solely due to strong dollar
- Covid vaccine sales came in well above analyst estimates
This article is for subscribers only.
Johnson & Johnson reported third-quarter earnings that beat analyst estimates as revenue grew in its drugs and medical-device businesses despite pressure from the stronger dollar.
The diversified health-care company, which is in the process of separating out its consumer division, reported sales results on Tuesday that were roughly in line with Wall Street’s estimates for the pharmaceutical and medical-device businesses that it is retaining.